Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sinomab Bioscience Limited has 2 pending office actions in Biotechnology & Pharmaceuticals. The work is assigned to 1 distinct examiner within 1 distinct art unit, indicating a tightly concentrated prosecution path rather than distribution across multiple examination groups.
FAUST, AMBER KATHLEEN is the busiest examiner and accounts for 2 pending actions. Because that figure matches the portfolio’s total pending actions, counsel can focus prosecution review on one examiner’s cited issues, amendment preferences, and response history.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAUST, AMBER KATHLEEN | 1 | 61.1% | +53.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | FAUST, AMBER KATHLEEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | FAUST, AMBER KATHLEEN | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701828 | AQUEOUS FORMULATIONS OF AN ANTI-CD22 ANTIBODY AND USES THEREOF | FAUST, AMBER KATHLEEN | 1643 | §102§103 | Non-Final OA | — | Pending | Apr 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSinomab Bioscience Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amber Kathleen Faust has the most, with 1 of Sinomab Bioscience Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
